Tea tree oil
CAS 68647-73-4
Tea tree oil (CAS 68647-73-4) is a pharmaceutical compound with 0 bioactivity targets and 18 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Tea tree oil is linked to DTXSID60100611 in DSSTox identifiers.
View industrial chemical data →Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| TEA TREE OIL | 69627 | SU | MTHSPL |
| Tea Tree Oil | 69627 | SU | MTHSPL |
| tea tree oil | 69627 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Tea tree oil used for in pharmaceutical contexts?
Tea tree oil (CAS 68647-73-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Tea tree oil?
Tea tree oil has 18 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Abdominal pain upper, Condition aggravated, Death, Drug effective for unapproved indication, Dyschezia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Tea tree oil also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Melaleuca Alternifolia (Tea Tree) Leaf Oil with EU status "permitted".
What clinical phase is Tea tree oil in?
No phase 1-4 clinical development badge is rendered for Tea tree oil because the matched compound identifier rows do not contain a max-phase value.